Table 1.
The correlation of visfatin (NAMPT) with cancer patient survival
| Symbol | Cancer type | Prognosis | Endpoint | p-value | Cases | Dataset/cohort | Method | Probe ID |
|---|---|---|---|---|---|---|---|---|
| NAMPT | Bladder urothelial carcinoma | – | Overall survival | N.S. | 390 | TCGA | RNA sequencing | |
| NAMPT | Glioblastoma multiforme | Poor | Overall survival | 0.001 | 538 | TCGA | RNA sequencing | |
| NAMPT | Breast invasive carcinoma | – | Overall survival | N.S. | 962 | TCGA | RNA sequencing | |
| NAMPT | Cervical squamous cell carcinoma | – | Overall survival | N.S. | 191 | TCGA | RNA sequencing | |
| NAMPT | Colon and rectum adenocarcinoma | – | Overall survival | N.S. | 467 | TCGA | RNA sequencing | |
| NAMPT | Esophageal carcinoma | – | Overall survival | N.S. | 184 | TCGA | RNA sequencing | |
| NAMPT | Uveal melanoma | – | Overall survival | N.S. | 80 | TCGA | RNA sequencing | |
| NAMPT | Head and neck squamous cell carcinoma | Poor | Overall survival | 0.0048 | 502 | TCGA | RNA sequencing | |
| NAMPT | Acute myeloid leukemia | – | Overall survival | N.S. | 168 | TCGA | RNA sequencing | |
| NAMPT | Kidney PAN cancer | Poor | Overall survival | 0.0159 | 792 | TCGA | RNA sequencing | |
| NAMPT | Liver hepatocellular carcinoma | – | Overall survival | N.S. | 361 | TCGA | RNA sequencing | |
| NAMPT | Lung adenocarcinoma | – | Overall survival | N.S. | 475 | TCGA | RNA sequencing | |
| NAMPT | Ovarian serous cystadenocarcinoma | – | Overall survival | N.S. | 578 | TCGA | RNA sequencing | |
| NAMPT | Pancreatic adenocarcinoma | – | Overall survival | N.S. | 176 | TCGA | RNA sequencing | |
| NAMPT | Prostate adenocarcinoma | – | Overall survival | N.S. | 497 | TCGA | RNA sequencing | |
| NAMPT | Skin cutaneous melanoma | – | Overall survival | N.S. | 336 | TCGA | RNA sequencing | |
| NAMPT | Stomach adenocarcinoma | – | Overall survival | N.S. | 352 | TCGA | RNA sequencing | |
| NAMPT | Testicular germ cell tumors | – | Overall survival | N.S. | 133 | TCGA | RNA sequencing | |
| NAMPT | Thymoma | Poor | Overall survival | 0.0226 | 118 | TCGA | RNA sequencing | |
| NAMPT | Thyroid carcinoma | – | Overall survival | N.S. | 489 | TCGA | RNA sequencing | |
| NAMPT | Uterine corpus endometrioid carcinoma | – | Overall survival | N.S. | 332 | TCGA | RNA sequencing | |
| NAMPT | Breast cancer | Poor | Relapse-free survival | 0.0022 | 3951 | E-MTAB-365, E-TABM-43, GSE: 11,121, 12,093, | Array | 217739_s_at |
| 12,276, 1,456, 16,391, 16,446, 16,716, 17,705, 17,907, | ||||||||
| 18,728, 19,615, 20,194, 20,271, 2,034, 20,685, 20,711, | ||||||||
| 21,653, 2,603, 26,971, 2,990, 31,448, 31,519, 32,646, | ||||||||
| 3,494, 37,946, 41,998, 42,568, 45,255, 4,611, 5,327, | ||||||||
| 6,532, 7,390, 9,195 | ||||||||
| NAMPT | Ovarian cancer | Poor | Post progression survival | 0.043 | 782 | GSE: 14,764, 15,622, 18,520, 19,829, 23,554, 26,193, | Array | 217739_s_at |
| 26,712, 27,651, 30,161, 3,149, 51,373, 63,885, 65,986, | RNA sequencing | |||||||
| 9,891, TCGA (N=565) | ||||||||
| NAMPT | Lung cancer | – | Post progression survival | N.S. | 344 | CAARRAY, GSE: 14,814, 19,188, 29,013, 30,219, | Array | 217739_s_at |
| 31,210, 3,141, 31,908, 37,745, 43,580, 4,573, 50,081, | RNA sequencing | |||||||
| 8,894, TCGA (N=133) | ||||||||
| NAMPT | Gastric cancer | Good | Post progression survival | <0.0001 | 499 | GSE: 14,210, 15,459, 22,377, 29,272, 51,105, 62,254 | Array | 217739_s_at |
Note: Survival data were collected from SurvExpress, The Cancer Genome Atlas (TCGA) and Kaplan–Meier plotter database.
Abbreviations: NAMPT, nicotinamide phosphoribosyltransferase (visfatin); N.S., no significance; GSE, Gene Expression Omnibus (GEO) Series.